National Health Determination under paragraph 98C(1)(b) Amendment 2017 (No. 4) (PB 36 of 2017) (Cth)

PB 36 of 2017

National Health Determination under paragraph 98C(1)(b) Amendment 2017
(No. 4)

_____________________________________________________________________

I, PENNY SHAKESPEARE, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Instrument under paragraph 98C(1)(b) of the National Health Act 1953.

Dated 30 May 2017

PENNY SHAKESPEARE

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health

1              Name of Instrument

(1)This Instrument is the National Health Determination under paragraph 98C(1)(b) Amendment 2017 (No. 4).

(2)This Instrument may also be cited as PB 36 of 2017.

2              Commencement  

This instrument commences on 1 June 2017.

3              Amendments to Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008)

Schedule 1 amends the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008).

Schedule 1            Amendments

1. Schedule 4, omit entry for Colestipol

1. Schedule 4

omit:

Epoprostenol	Powder for I.V. infusion 500 micrograms (as sodium) with 2 vials diluent 50 mL
Powder for I.V. infusion 1.5 mg (as sodium) with 2 vials diluent 50 mL

1. Schedule 4, after entry for Fluticasone in the form Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms per dose, 60 doses

insert:

Fluticasone furoate with vilanterol	Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses
Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses

1. Schedule 4

omit:

Fluticasone with vilanterol	Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses
Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses

1. Schedule 4

omit:

Leuprorelin I.M. injection (3 month modified release), powder for injection containing leuprorelin acetate 30 mg with diluent in pre-filled dual-chamber syringe

1. Schedule 4, entry for Salbutamol

insert as first item in the column headed “Form (strength, type, size, etc.)”:

Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20